CG Oncology (CGON) Treasury Shares (2023 - 2026)

CG Oncology (CGON) posted Treasury Shares of $165373.0 for Q1 2026, down 0.58% on a QoQ basis from $166342.0 in Q4 2025.

CG Oncology (CGON) Treasury Shares (2023 - 2026) Analysis & Trends

CG Oncology's Treasury Shares history runs 3 years deep, the most recent figure standing at $165373.0 for Q1 2026.

Quarterly Treasury Shares changed N/A year-over-year to $165373.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165373.0 (changed N/A YoY) and the FY2025 annual result came in at $166342.0, changed N/A from the prior year.
Treasury Shares was $165373.0 for Q1 2026 at CG Oncology, down from $166342.0 in the prior quarter.
Across five years, Treasury Shares topped out at $73.6 million in Q2 2023 and bottomed at $94624.0 in Q3 2025.
A 3-year average of $29.2 million and a median of $23.9 million in 2023 frame the typical range for Treasury Shares.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	CG Oncology	6.01 Bn	6.01 Bn	-1.88 Mn	165,373.00

Download Data